Inhibitex 8-K 2009
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Item 3.02 Unregistered Sales of Equity Securities.
On October 29, 2009, Inhibitex, Inc. (the "Company") issued a press release announcing the completion of the Company’s previously announced private placement of units, each consisting of one share of common stock and a warrant to purchase 0.45 of a share of common stock , at a price of $1.28 per unit, or $23 million in the aggregate. In the offering, the Company issued an aggregate of 17,968,747 shares of its common stock and warrants to purchase an aggregate of 8,085,932 shares of its common stock. The warrants expire on October 28, 2013 and have an exercise price of $1.46 per share. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 8.01 Other Events.
The press release dated October 29, 2009, announcing the completion of the private placement finacing is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.